ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies
Sep 26
2024
热门爆料. (2024).
ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies.
Retrieved from /advocacy/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies.
热门爆料.
"ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies." Hematology.org.
/advocacy/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies
(label-accessed June 15, 2025).
"热门爆料."
ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies, 15 Jun. 2025 ,
/advocacy/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies.
